Cor a 9 Allergen Isolation for Hazelnut Systemic Reaction Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating hazelnut-induced systemic allergic reactions are incomplete, as they do not adequately identify the specific allergens responsible for non-tree pollen-associated hazelnut allergies, leading to inadequate diagnosis and treatment.
Innovation Solution
Identification of the hazelnut allergen Cor a 9, an 11S globulin, which is predictive for hazelnut allergy characterized by systemic reactions, along with the development of methods for diagnosing and treating hazelnut allergy using isolated nucleic acids, polypeptides, and peptides comprising epitopes of Cor a 9, including expression vectors, host cells, and immunotherapy compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used for hazelnut allergy, then general allergic reactions can be detected, but specific identification of non-tree pollen-associated hazelnut allergens is incomplete
Solution Approach 1:
The patent extracts and isolates the specific Cor a 9 allergen from hazelnut proteins through purification processes. This extraction allows for targeted identification of the specific allergen responsible for non-tree pollen-associated hazelnut allergies, separating it from other hazelnut proteins and allergens that do not cause the same reaction pattern.
Solution Approach 2:
The patent segments the hazelnut allergen profile into distinct components, specifically identifying Cor a 9 as a separate entity from other hazelnut allergens like Cor a 1. This segmentation enables differentiated diagnosis between tree pollen-associated and non-tree pollen-associated hazelnut allergies through specific immunological testing for Cor a 9.
2Adaptability or versatility
If hazelnut allergy diagnosis is expanded to include all reaction types, then more patients are identified, but the complexity of allergen identification increases
Solution Approach 1:
The patent develops a universal diagnostic approach using Cor a 9-specific immunological tests that can identify non-tree pollen-associated hazelnut allergies across different patient populations. This single specific allergen marker serves multiple diagnostic purposes, including distinguishing severe systemic reactions from mild oral allergy syndrome, without requiring complex multi-allergen panels for each case.
3Reliability
If specific hazelnut allergens are identified for targeted therapy, then treatment effectiveness improves, but the complexity of allergen characterization increases
Solution Approach 1:
The patent applies extraction and purification techniques to isolate Cor a 9 from hazelnut proteins, creating a standardized allergen product for immunotherapy. This purified Cor a 9 can be used consistently across treatment protocols, ensuring reliable and reproducible treatment effectiveness without requiring complex characterization processes at each treatment facility.
Solution Approach 2:
The patent utilizes specific immunological parameters (IgE binding patterns, serum reactivity profiles) to characterize Cor a 9. By focusing on these specific measurable parameters rather than comprehensive structural characterization, the patent achieves reliable allergen identification and treatment standardization with manageable complexity.
Data Source
AI summary
The present invention is directed to methods for predicting or diagnosing a hazelnut-induced systemic reaction, and for methods for treating such a reaction.